Search results for "Progression"

showing 10 items of 1251 documents

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

2019

Abstract Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-bas…

AdultOncologymedicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsVinorelbineDrug Administration ScheduleAntineoplastic AgentEfficacyCapecitabine03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalCyclophosphamideRetrospective StudiesAgedAged 80 and overAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerMetronomic ChemotherapySurvival RateMethotrexateTreatment Outcome030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAFemaleSurgerybusinessBreast NeoplasmHumanmedicine.drugThe Breast
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Societe de Pneumo…

2016

Revue des Maladies Respiratoires - In Press.Proof corrected by the author Available online since samedi 16 avril 2016

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescent[SDV]Life Sciences [q-bio]MEDLINEYoung Adult03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesPulmonary medicinePulmonary MedicinemedicineHumansAsthmatic patient030212 general & internal medicineYoung adultChildSocieties MedicalComputingMilieux_MISCELLANEOUSMonitoring PhysiologicAsthmaAsthma therapy[ SDV ] Life Sciences [q-bio]business.industryDisease progressionasthmamedicine.disease3. Good healthasthme[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030228 respiratory systemDisease ProgressionFrancebusiness
researchProduct

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

2008

Established histopathological criteria divide invasive breast carcinomas into defined groups. Ductal of no specific type and lobular are the two major subtypes accounting for around 75 and 15% of all cases, respectively. The remaining 10% include rarer types such as tubular, cribriform, mucinous, papillary, medullary, metaplastic, and apocrine breast carcinomas. Molecular profiling technologies, on the other hand, subdivide breast tumors into five subtypes, basal-like, luminal A, luminal B, normal breast tissue-like, and ERBB2-positive, that have different prognostic characteristics. An additional subclass termed "molecular apocrine" has recently been described, but these lesions did not ex…

AdultSilver StainingBreast NeoplasmsBiologyProteomicsBiochemistrySubclassAnalytical ChemistryImmunophenotypingCohort StudiesBreast cancerCoenzyme A LigasesmedicineBiomarkers TumorHumansElectrophoresis Gel Two-DimensionalNeoplasm Invasivenessskin and connective tissue diseasesMolecular BiologyAgedAged 80 and overTissue microarrayParaffin EmbeddingApocrineMiddle Agedmedicine.diseaseImmunohistochemistryApocrine GlandsPhenotypeTissue Array AnalysisImmunologyCancer researchDisease ProgressionHydroxyprostaglandin DehydrogenasesImmunohistochemistryFemaleApocrine CellBreast carcinomaMolecularcellular proteomics : MCP
researchProduct

Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.

2009

Hurler-Scheie syndrome is caused by alpha-l-iduronidase deficiency. Enzyme replacement therapy (ERT) can improve physical capacity and reduces organomegaly. However, the effect on bradytrophic connective tissue is limited. As intravenously administered enzyme cannot cross the blood-brain barrier, the therapy of choice for the more severe Hurler syndrome is haematopoietic stem cell transplantation (HCT). In the more attenuated Scheie syndrome, neurological impairment is less severe; therefore, ERT may be appropriate to treat these patients. Information on long-term outcome in Scheie patients undergoing ERT is scarce. We report a 38-year-old female Scheie patient who has been on ERT for 8 yea…

Adultcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis IMyelopathyIduronidaseSpinal cord compressionMucopolysaccharidosis IGeneticsmedicineHumansEnzyme Replacement TherapyHurler syndromeGenetics (clinical)business.industryHematopoietic Stem Cell Transplantationnutritional and metabolic diseasesBrainEnzyme replacement therapymedicine.diseaseSpinal cordSurgeryTransplantationmedicine.anatomical_structureCervical VertebraeDisease ProgressionFemaleScheie syndromebusinessSpinal Cord CompressionJournal of inherited metabolic disease
researchProduct

Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes

2002

Patients with type 1 diabetes mellitus and microalbuminuria often have elevated blood pressure while they are asleep, but it is not known whether the elevation develops concomitantly with microalbuminuria or precedes it.We monitored 75 adolescents and young adults who had had type 1 diabetes with normal urinary albumin excretion and blood pressure for more than five years. Ambulatory blood-pressure monitoring was used to assess blood pressure at the initial evaluation and about two years later, at which time all subjects had normal urinary albumin excretion. Subsequently, subjects were monitored for the development of microalbuminuria.Microalbuminuria developed in 14 subjects, whereas the o…

Adultmedicine.medical_specialtyAdolescentBlood PressureExcretionInternal medicineDiabetes mellitusmedicineAlbuminuriaHumansProspective StudiesGlycated HemoglobinType 1 diabetesProteinuriabusiness.industryAlbuminGeneral MedicineBlood Pressure Monitoring Ambulatorymedicine.diseaseCircadian RhythmDiabetes Mellitus Type 1EndocrinologyBlood pressureAmbulatoryDisease ProgressionCardiologyMicroalbuminuriamedicine.symptombusinessBiomarkersNew England Journal of Medicine
researchProduct

Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients.

2017

IntroductionRepeated haemarthrosis is widely accepted as the triggering cause of synovitis and haemophilic arthropathy. A first-line treatment of chronic synovitis is radiosynoviorthesis (RS). The aim of this study was to evaluate the RS effects on the progression of arthropathy and on a reduction in bleeding in patients with haemophilia. MethodsAn observational-retrospective study was performed. Bleeding episodes in the 12months following and in the 12months preceding RS was compared. The arthropathy was clinically and radiologically analysed by age range, joint and subject, comparing those undergoing RS (Radiosynoviorthesis Group, RSG) against those not undergoing this treatment (Non-Radi…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatment030204 cardiovascular system & hematologyHaemophiliaHemophilia AGastroenterologyradiosynoviorthesis03 medical and health sciencesYoung Adult0302 clinical medicinehaemarthrosisSynovectomyInternal medicineSynovitisArthropathyElbow JointHemarthrosismedicineHumansIn patientYttrium RadioisotopesGenetics (clinical)Reduction (orthopedic surgery)Retrospective StudiesRadioisotopesHaemophilic arthropathyBleeding episodesSynovitisbusiness.industryShoulder Jointhaemophilic arthropathyHematologyGeneral MedicineMiddle Agedmedicine.diseaseChronic synovitisRheniumTreatment OutcomeDisease ProgressionJoint DiseasesbusinesssynovitisAnkle Joint030215 immunologyHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Achievement of treatment targets predicts progression of vascular complications in type 1 diabetes.

2021

Abstract Background and aim To study the association between achievement of guideline-defined treatment targets on HbA1c, low-density lipoproteins (LDL-C), and blood pressure with the progression of diabetic complications in patients with type 1 diabetes (T1D). Methods The study included 355 patients at baseline and 114 patients with follow-up data after 3–5 years. Outcome variables were the progression of diabetic kidney disease, retinopathy, or cardiovascular disease (CVD). We used logistic regression and other machine learning algorithms (MLA) to model the association of achievement of treatment targets and probability of progression of complications. Results Achievement of the target bl…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDiseaseLogistic regressionOddsDiabetes ComplicationsMachine LearningEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansDiabetic NephropathiesGlycated HemoglobinType 1 diabetesbusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseLatviaBlood pressureDiabetes Mellitus Type 1Treatment OutcomeCardiovascular DiseasesHypertensionDisease ProgressionComplicationbusinessRetinopathyFollow-Up StudiesJournal of diabetes and its complications
researchProduct

Pregnancy outcomes in women with advanced HIV infection in Italy

2011

Pregnancy has been associated with a low risk of HIV disease progression. Most pregnancies with HIV currently involve women who have not experienced AIDS-defining events, and are clinically classified as Centers for Disease Control and Prevention (CDC) groups A or B. We evaluated the main maternal outcomes among pregnant women with more advanced HIV disease, defined by CDC-C disease stage. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used. A total of 566 HIV-infected mothers, 515 in stage A or B (CDC-AB group) and 51 in stage C (CDC-C group) were evaluated. The two groups had similar baseline characteristics. No differences were found …

Adultmedicine.medical_specialtyGestational AgeHIV InfectionsDiseaseSettore MED/17 - MALATTIE INFETTIVESeverity of Illness IndexYoung AdultAcquired immunodeficiency syndrome (AIDS)ANTIRETROVIRAL THERAPYRisk FactorsPregnancyAntiretroviral Therapy Highly ActiveSeverity of illnessmedicineHumansPregnancy Complications InfectiousYoung adultPregnancyObstetricsbusiness.industryClinical and Epidemiologic ResearchPregnancy OutcomePublic Health Environmental and Occupational HealthHIVGestational ageLiterMiddle AgedViral Loadmedicine.diseaseinfectionCD4 Lymphocyte CountLogistic ModelsInfectious DiseasesAnti-Retroviral AgentsItalyImmunologyHUMAN-IMMUNODEFICIENCY-VIRUSDisease ProgressionFemalebusinessViral load
researchProduct

Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study

2016

Study Objective To assess the feasibility of total robotic radical surgery (TRRS) in patients with locally advanced cervical cancer (LACC) who receive chemoradiation therapy (CT/RT). Design A prospective (preplanned) study of a nonrandomized controlled trial (Canadian Task Force classification level 2). Setting Catholic University of the Sacred Hearth, Rome, Italy. Patients Between September 2013 and January 2016, a total of 40 patients with LACC (Fédération Internationale de Gynécologie et d'Obstétrique stage IB2–III) were enrolled in the study. Interventions Robotic radical hysterectomy (RRH) plus pelvic and/or aortic lymphadenectomy was attempted within 6 weeks after CT/RT. The feasibili…

Adultmedicine.medical_specialtyLocally advancedPhases of clinical researchUterine Cervical NeoplasmsChemoradiation; Locally advanced cervical cancer; Robotic radical hysterectomyHysterectomy03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRobotic Surgical ProceduresRobotic radical hysterectomymedicineHumansIn patientRadical surgeryRadical HysterectomyChemoradiation; Locally advanced cervical cancer; Robotic radical hysterectomy; Obstetrics and GynecologyAgedCervical cancerLocally advanced cervical cancer030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseCombined Modality TherapySurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAChemoradiation030220 oncology & carcinogenesisConcomitantCarcinoma Squamous CellDisease ProgressionFeasibility StudiesLymph Node ExcisionFemaleLaparoscopybusiness
researchProduct